Clinical Trials in Shinagawa-ku, Tokyo
9 recruiting
Showing 1–9 of 9 trials
Recruiting
Phase 3
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A Nephropathy (IgAN)
Biogen454 enrolled233 locationsNCT06935357
Recruiting
Phase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
ObesityHeart Failure With Preserved Ejection FractionHeart Failure With Mildly Reduced Ejection Fraction
Amgen5,056 enrolled603 locationsNCT07037459
Recruiting
Phase 3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
AbbVie698 enrolled316 locationsNCT04928846
Recruiting
Specified Drug-use Surveillance of Fabhalta Capsules
Paroxysmal nocturnal hemoglobinuria
Novartis Pharmaceuticals100 enrolled92 locationsNCT06606314
Recruiting
Entresto Tablets and Granules for Pediatric Specified Drug-use Survey (Pediatric Chronic Heart Failure)
Pediatric Chronic Heart Failure
Novartis Pharmaceuticals30 enrolled28 locationsNCT06659393
Recruiting
Not Applicable
A Clinical Evaluation of AMJ-401
Ischemic Heart Disease (IHD)
Abbott Medical Devices50 enrolled10 locationsNCT07373353
Recruiting
Phase 3
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Myelodysplastic SyndromeAnemia
Takeda300 enrolled146 locationsNCT07422480
Recruiting
Phase 3
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
Regeneron Pharmaceuticals190 enrolled69 locationsNCT05133531
Recruiting
Phase 2
Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer
Recurrent Triple-Negative Breast Cancer
Yukinori Ozaki44 enrolled15 locationsNCT06976944